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Abstract
The objective of this study was to identify the impact of professional knowledge and
education on a willingness to participate in clinical trials. It hypothesized that there is no
statistical difference in the median rank score between clinical research professionals and
other post-graduate educated participants. The research question asked whether the
clinical research program graduates were more inclined to participate in clinical trials than
other groups with a post-graduate education. A cross-sectional quantitative study of 83
clinical research professionals was conducted. All participants were invited to complete a
shortened version of the Center for Information and Study on Clinical Research
Participation (CISCRP) survey assessing their willingness to participate in clinical trials.
This study showed that there is a significant difference between the two groups. Although
some factors must be considered when determining their actual participation rate, these
findings should not discourage recruiting clinical research professionals into clinical trials.
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I. Introduction
A large proportion of research on potential participants within the clinical research
professionals remains incomplete. Patient recruitment targeted typical and more
traditional populations. However, clinical research professionals and the post-graduate
public with clinical knowledge are a considerable population to be studied. Knowledge of
the clinical research professionals’ willingness to participate in clinical trials might
enhance the diversity and effectiveness of recruitment. The objectives of this study were
to identify the impact of professional knowledge in clinical research in the willingness to
participate in clinical trials compared to other educated populations. This study aimed to
better understand the barrier of recruiting different human subjects into clinical research.
There is a lack of knowledge of clinical research professionals’ willingness to
participate in clinical trials. Observing the differences in willingness to participate in
clinical trials between the post-graduate public and clinical research professionals is
required. The assumption is that there is no statistical difference in the median rank score
between clinical research professionals and the other post-graduate participants.
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II. Review of Literature
Clinical trials are the application of exploring the updates of therapies and
preventions in medical science. Although the objective of the clinical trial is to deliver a
maximum expectation of care and to enrich science, a limited number of patients are
enrolled in clinical trials (Sood et al., 2009). One of the factors of success of clinical trials
is enrolling the target population of the intended treatment or prevention. According to
Sood et al. (2009), the assessment of patients’ perspectives of clinical studies indicates
that 68% responded positively to the idea of participating in clinical trials. However, 82%
were unaware of how to access information about clinical trials for their disease.
Therefore, recruitment of patients should be more efficient to update medical care and
disease prevention through the application of clinical trials.
Recruitment of patients for clinical trials has been getting attention in the clinical
research field recently. The processes of recruiting and retaining patients are becoming
more complicated, which delays drug development (Findlay, 2009). According to English,
Lebovitz and Giffin (2010), this delay is costing the clinical research industry money,
time, and resources, depending on the type of trial, populations, and research setting. The
overall estimate of the cost of delay is up to $300–$600 million to implement, conduct,
and monitor a large, multicenter trial to completion (Institute of Medicine [US]) Forum on
Drug Discovery, 2010). Speeding patients’ recruitment is attainable to enhance the overall
clinical trial enterprise by recognizing the factors of participation.
Willingness to participate in clinical trials is one of the factors of participation.
According to Gul and Ali (2010), most studies have focused on the willingness of patients
and their families to participate in clinical trials. However, a recent survey from the
2
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Center for Information and Study on Clinical Research Participation (CISCRP; 2015)
found that approximately 80% of the general population had a positive predilection to be
involved in clinical trials. These participants comprise a large part of the participants in
potential therapies and protection trials. Therefore, the public perspective and willingness
to participate are significant in the clinical trial enterprise.
Patients have various reasons for participating in clinical trials. According to
Brintnall-Karabelas et al. (2011) and Getz (2014), even if the participants are qualified to
enroll in the clinical trials, they have concerns about receiving placebo, adverse effects,
medical exposure, confidentiality, and unexpected costs. Interestingly, the CISCRP (2015)
revealed that 43% of the public perceived the side effects as a major risk of participating
in clinical trials, while only 28% related their contribution to helping medical science and
potential therapies. This result is similar to the Teschke et al. (2010) study, which showed
that possible medical advantages to the person or community encourage participation in
clinical trials. Respondents were highly concerned either their diseases or their relatives’
condition. Approximately 25% were unwilling to participate, while 29% were unsure
about contributing to clinical trials (Teschke et al., 2010). The public seems to consider
the benefits and risks before they join any clinical trials.
Willing and unwilling groups have different characteristics. According to Teschke
et al. (2010), the characteristics of willing participants included having a sick family
member, being elderly, prior involvement in clinical research, or having a positive
inclination toward clinical trial participation. Research results were also a great motivator.
However, the characteristics of unwilling respondents included post-graduate education
and an attitude, depending on the objective of the trial, toward clinical trial participation
3
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(Teschke et al., 2010). According to Nelson, Martin and Getz (2015), 18 - 34-year-olds
were the least willing to participate in clinical trials compared with older generations. In
addition, the younger generation had diverse concerns of health issues, such as weight
control, healthy lifestyle, and prevention of diseases, which were different than the
perception of the older generations (Nelson et al., 2015). The characteristics of willing
and unwilling participants vary based on their clinical trial perspectives, which determine
their willingness to participate.
In addition, willingness to participate in clinical trials differs from the public to
specific patient groups. As explained earlier, the public might consider their participation
as social contribution while patients might consider their health status before participation
in clinical trials. According to English, Lebovitz and Giffin (2010), patients have different
perceptions depending on their disease type and severity. Around 68% of patients were
willing to participate in clinical trials, while 82% were unfamiliar with the clinical trials
on their illness (Sood et al., 2009). Agoritsas, Deom and Perneger (2011) found that
patients appreciated the contribution of clinical trials if these trials were safe and suitable
and if they had adequate information from their physicians. Consequently, patients were
willing to participate in clinical trials if they had sufficient knowledge about the trials.
Research has shown that patients’ education about the research could enhance
their participation in clinical trials, but there is limited research on the level of education
as a factor associated with a willingness to participate in clinical trials. According to
Fayed (2016), the clinical trial type and complexity affect decisions to participate in
clinical trials. About 80% of healthcare providers surveyed were willing to participate in
clinical trials. However, they were more willing to participate in surveys than trials with
4
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intervention or new therapies for diseases. Also, a recent study by Bouida et al. (2016)
stated that 89% of physicians were willing to participate in clinical trials. The main
encouragement was enhancing science, while the largest reason for reluctance was the
complications. Despite the willingness of professionals to participate in clinical trials, the
level of education is a factor that distinguishes the public from professionals.
Similarly, the public, healthcare providers, or professionals were equally
concerned about the complications of the clinical trials. According to Fayed (2016),
87.2% of healthcare providers were concerned about adverse events, and 79.5% had
issues about the endpoints of clinical trials. Despite their background, they were hesitant
about the significance behind these clinical trials. Although there is a lot of research on
public perception, professional willingness to participate in clinical trials needs more
attention.
According to the literature, there is a lack of knowledge about clinical research
professionals’ willingness to participate in clinical trials. Earlier literature concentrated on
patients, patients’ families, patients at risk, and the general public’s willingness to
participate in clinical trials. However, only a limited number of studies reported how
willing professionals are to participate in clinical trials. Therefore, there is a need to
investigate the willingness of clinical research professionals to participate in clinical trials.
Studying clinicians or professionals and their willingness to participate in clinical
trials will help researchers recognize if there is potential for new volunteers with new
perceptions and experiences, or if a potential specialty could affect the willingness to
participate in clinical trials. The assumption is that clinical research professionals would

5
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be as willing to participate in clinical trials as the public. This study aims to observe the
differences, if they occur, in willingness to participate in clinical trials between
individuals with a post-graduate education and clinical research professionals. The postgraduate population from the CISCRP (2015) was compared to alumni of the Clinical
Research Administration Graduate Program of Eastern Michigan University.

6
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III. Research Design and Methodology
Research Question
Are clinical research administration program graduates more inclined to
participate in clinical trials than other groups with a post-graduate education?
Research Objective
The objectives of this study were to identify the impact of professional knowledge
and education on a willingness to participate in clinical trials.
Research Hypothesis
There is no statistical difference in the median rank score between clinical
research professionals and other post-graduate educated participants.
Research Subjects
Respondents with a post-graduate education in the Center for Information and
Study on Clinical Research Participation (CISCRP) study were compared to clinical
research professionals who were 2000 to 2015 alumni of the clinical research
administration graduate program at Eastern Michigan University. Differences in
willingness to participate in clinical trials were evaluated. Current students who have not
yet graduated from the CRA program were excluded. The CRA respondents were 97.59%
USA residents; therefore, they were compared to the US post-graduate participants of the
CISCRP survey.
Research Methods
CISCRP database. The CISCRP, an independent nonprofit organization,
conducted an online international survey in 2015, titled ‘‘The 2015 CISCRP Perceptions

7
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& Insights Study: Report on General Perceptions.’’ The study presents valued and
substantive insights into actionable ways that stakeholders of the clinical trials can better
comprehend and more adequately engage with the general population and study
participants. The overall results and subgroup differences are presented by demographic
data, education level, income, age, and severity of the disease.
The total number of survey respondents to the CISCRP survey was more than
12,000 people. The US residents and post-graduates (e.g. master’s or doctorate level
degrees) of the CISCRP numbered 560 participants. The aggregated data of the subgroup
was obtained from CISCRP and compared to the data of the CRA study focusing on one
question of importance: How willing are you to participate in a clinical research study?
There were five survey responses options: I am not sure, not at all willing, not very
willing, somewhat willing, very willing, and I am not sure.
CRA data. A cross-sectional quantitative study of a purposive sample of 419
clinical research professionals derived from the clinical research administration
department database was approved by the University Human Subjects Review Committee
(UHSRC) of Eastern Michigan University. See Appendix A. The number of respondents
totaled 83 participants or approximately 20% of the purposive sample. Of the respondents,
67.47% were employed in clinical research. All participants were invited to complete a
shortened version of the CISCRP published survey after giving consent to participate in
the study. The informed consent document is in Appendix B. The survey was open for
two weeks. See Appendix C for the survey.

8
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The first part of the electronic survey queried demographic data such as residency,
age, race, gender, employment status, occupation, and income. The second part of the
survey assessed willingness to participate in clinical trials. It involved a question about
willingness to participate in clinical trials as a research subject. There were five survey
responses options: I am not sure, not at all willing, not very willing, somewhat willing,
very willing, and I am not sure. In addition, a question was posed regarding their efforts to
join a clinical trial, and actual participation. This question was a direct yes or no question.
Other detailed questions examined the reasons that most people participate in clinical
trials, how these people perceive clinical research, and what kind of information they need
to participate as a research subject. Participants were required to evaluate their level of
agreement to some statements. In addition, one question determined the perception of the
level of safety of clinical trials by asking participants to state one of the following
answers: very safe, somewhat safe, not very safe, or not at all safe. Finally, participants
were asked to specify possible benefits and risks of participating in clinical trials.
Data Management
Data were collected from Survey Monkey and exported to a secured Microsoft
Excel file. The secured file was double locked, including passwords for the laptop and
Microsoft Excel file. The survey instrument itself did not collect any personal
identification information. Statistical analyses were conducted using IBM SPSS Statistics
24, and the data were exclusively aggregated. Several different statistical tests were also
conducted on the data of this study: a set of Spearman’s correlations, several chi-square
analyses, and odds ratio calculation.

9
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The Spearman's rank-order correlation (often abbreviated to Spearman's
correlation) calculates a coefficient, rs or ρ, which is a measure of the strength and
direction of the association between two continuous or ordinal variables. It is also, a
measure of the significance of the relationship between two measures, which can be
ordinal, interval, or ratio. Spearman’s rho can vary from -1 to +1, with -1 indicating a
perfect negative correlation, zero indicating no correlation, and +1 indicating a perfect
positive correlation. This test was chosen to determine whether there is an association
between safety, age, willingness to patriciate in clinical trials, and other ordinal variables
among CRA participants.
Several one-sample chi-square analyses were conducted on these data. This test is
used in order to determine whether there is a significant difference between responses
given to some question; these responses are categorical, and some expected distribution.
This test compares the actual responses provided by individuals with the expected
distribution, which is specified by the researcher, in order to determine whether these two
distributions are significantly different.
In addition, an odds ratio was calculated in the dataset question of CRA graduates
or post-graduates CISCRP. It is a measure of association between an exposure and an
outcome; the ratio of the probability that an event will occur to the probability that it will
not occur, and it can be any number between zero and infinity. The odds ratio was
calculated focusing upon the measure of willingness or unwillingness and its relationship
with the dataset in the willingness question. Within the context of the current study, this
odds ratio showed how much more likely respondents are to be willing to participate in
clinical trials among those in the post-graduates CISCRP as compared with those in the
10
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CRA graduates group. This odds ratio provided information about the association between
these two measures over and above that obtained from a simple cross tabulation or chisquare test.
Participants’ Consent
Participants were introduced to the study survey through an invitation E-mail
(Appendix D and E) which included the following: study title, study objectives, study
procedure, voluntary rights, expected risks, expected benefits, dissemination of results,
confidentiality, and contact information. See Appendix B for informed consent.
Therefore, participants who were willing to participate followed the hyperlink to the
survey in the E-mail. The introductory page of the survey covered the consent information
of participating in the intended study and the voluntary rights to completing the survey.
Confidentiality
The survey was anonymous. The researcher and statistician involved in this study
had access to the responses. Otherwise, information provided was compiled with other
scores and turned into statistical data.
Ethical Aspects
The University Human Subjects Review Committee (UHSRC) of Eastern
Michigan University reviewed and approved this study before the research was
conducted. See Appendix A.

11
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IV.

Results

Spearman’s Correlation
Four hundred and eleven CRA graduates were invited to participate in the current
study, among which 83 participants accepted to join the study; the response rate was 20%.
The objective of the study was to identify the impact of professional knowledge and
education on willingness to participate in clinical trials. Theresore, a series of Spearman
rank order correlation were performed on the ordinal variables to assess the association
between the perception of the safety of the clinical research and the willingness to
participate in clinical trials among graduates of Eastern Michigan University clinical
research administration program, and the other study variables. A summary of the results
can be found in Table 1.

12
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Table 1 Spearman’s Correlations
Spearman’s Correlations

In the correlations conducted with the safety of clinical trials, three significant
correlations were found in total. The correlation between the participant's perception of
the safety of the clinical research and willingness to participate was a strong positive
(Cohen, 1988): rs(76) = .503, (p = .001). A weak positive correlation (rs = .279,
p = 0.013, df = 76) was found between the participant's perception of the safety of the
clinical research and their age. The correlation between the participant's perception of the
safety of the clinical research and how much time is spent at doctor's office was a weak
positive (rs = .008, p = 0.947, df = 77). A weak positive correlation (rs = .137, p = 0.233,
df = 76) was found between the participant's perception of the safety of the clinical
research and receiving more time and attention from medical experts. The correlation was

13
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a weak positive (rs = .105, p = 0.362, df = 76) between the participant's perception of the
safety of the clinical research and potential risks and benefits of the study. A weak
negative correlation (rs = -.087, p = 0.448, df = 76) was found between the participant's
perception of the safety of the clinical research and the length of research participation.
Similarly, a weak negative correlation (rs = -.054, p = 0.638, df = 76) was found between
the participant's perception of the safety of the clinical research and the types of medical
procedures of the research. The correlation was a weak positive (rs = .032, p = 0.748,
df = 76) between the participant's perception of the safety of the clinical research and
potential risks and the purpose of the clinical research study. A weak positive correlation
(rs = .094, p = 0.416, df = 75) was found between the participant's perception of the safety
of the clinical research and no risks are involved in the research. The correlation was a
weak positive (rs = .074, p = 0.524, df = 75) between the participant's perception of the
safety of the clinical research and doctor’s recommendation. A weak positive correlation
(rs = .198, p = 0.085, df = 75) was found between the participant's perception of the safety
of the clinical research and free treatment. The correlation was moderate positive
(rs = .335, p = 0.003, df = 75) between the participant's perception of the safety of the
clinical research and the convenience of the participation.
In the correlations conducted with the willing to participate in clinical trials, four
significant correlations were found. The correlation was a weak positive (rs = .289,
p = 0.011, df = 74) between the participants’ willingness to participate in clinical trials and
'their age. The correlation between the participants’ willingness to participate in clinical
trials and how much time is spent at doctor's office was a weak positive (rs = .272,
p = 0.016, df = 76). A weak positive correlation (rs = .146, p = 0.206, df = 75) was

14
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found between the participants’ willingness to participate in clinical trials and receiving
more time and attention from medical experts. The correlation was a weak positive
(rs = .109 p = 0.343, df = 76) between the participants’ willingness to participate in
clinical trials and potential risks and benefits. A weak negative correlation (rs = -.185,
p = 0.105, df = 76) was found between the participants’ willingness to participate in
clinical trials and the length of research participation. Similarly, a weak negative
correlation (rs = -.051, p = 0.657, df = 76) was found between the participants’
willingness to participate in clinical trials and the types of medical procedures of the
research. The correlation was a weak positive (rs = .101 p = 0.378, df = 76) between the
participants’ willingness to participate in clinical trials and the purpose of the clinical
research study. A weak positive correlation (rs = .138, p = 0.232, df = 75) was
found between the participants’ willingness to participate in clinical trials and no risks are
involved in the research. The correlation was a weak positive (rs = .200 p = 0.080,
df = 75) between the participants’ willingness to participate in clinical trials and doctor’s
recommendation. A moderate positive correlation (rs = .303, p = 0.007, df = 75) was
found between the participants’ willingness to participate in clinical trials and free
treatment. The correlation was a weak positive (rs = .245 p = 0.032, df = 75) between the
participants’ willingness to participate in clinical trials and the convenience of the
participation.
In the correlations conducted with particpants’ age, one significant correlation was
found in total. A weak positive correlation (rs = .106, p = 0.357, df = 75) was found
between the participant's age and how much time is spent at doctor's office. The
correlation was a weak positive (rs = .084 p = 0.472, df = 74) between the participant's
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age and receiving more time and attention from medical experts. A weak positive
correlation (rs = .076, p = 0.512, df = 74) was found between the participant's age and
potential risks and benefits. A weak negative correlation (rs = -.040, p = 0.729, df = 74)
was found between the participant's age and the length of research participation. The
correlation was weak positive (rs = .0954 p = 0.412, df = 74) between the participant's age
and the types of medical procedures of the research. The correlation between the
participant's age and the purpose of the clinical research study was a weak positive
(rs = .101 p = 0.378, df = 76). A weak positive correlation (rs = .176, p = 0.132, df = 73)
was found between the participant's age and no risks are involved in the research. The
correlation was a weak positive (rs = .013 p = 0.912, df = 73) between the participant's
age and doctor’s recommendation. A weak positive correlation (rs = .074, p = 0.526,
df = 73) was found between the participant's age and free treatment. The correlation
between the participant's age and the convenience of the participation was a weak positive
(rs = .031 p = 0.793, df = 73).
In the correlations conducted with the time spent in doctor's office, one significant
correlation was found in total. A moderate positive correlation (rs = .330, p = 0.003,
df = 76) was found between how much time is spent at the doctor's office and receiving
more time and attention from medical experts. The correlation between how much time is
spent at doctor's office and potential risks and benefits was a weak positive (rs = .004,
p = 0.971, df = 76). The correlation was a weak positive (rs = .043 p = 0.710, df = 76)
between how much time is spent at doctor's office and the length of research participation.
A weak positive correlation (rs = .062, p = 0.592, df = 76) was found between how much
time is spent at doctor's office and the types of medical procedures of the research. A

16

CLINICAL RESEARCH PROFESSIONALS PARTICIPATE IN CLINICAL TRIALS

weak negative correlation (rs = -.105, p = 0.358, df = 76) was found between how much
time is spent at doctor's office and the purpose of the clinical research study. The
correlation was a weak positive (rs = .201 p = 0.079, df = 75) between how much time is
spent at doctor's office and no risks are involved in the research. A weak negative
correlation (rs = -.048, p = 0.678, df = 75) was found between how much time is spent at
doctor's office and doctor’s recommendation. Similarly, a weak negative correlation
(rs = -.006, p = 0.961, df = 75) was found between how much time is spent at doctor's
office and free treatment. The correlation between how much time is spent at doctor's
office and the convenience of the participation was a weak positive (rs = .090 p = 0.435,
df = 75).
In the correlations conducted with receiving more time and attention from medical
experts, two significant correlations were found in total. The correlation was a weak
positive (rs = .158 p = 0.170, df = 75) between receiving more time and attention from
medical experts and potential risks and benefits. A weak positive correlation (rs = .154,
p = 0.182, df = 75) was found between receiving more time and attention from medical
experts and the length of research participation. Similarly, a weak positive correlation
(rs = .219, p = 0.056, df = 75) was found between receiving more time and attention from
medical experts and the types of medical procedures of the research. The correlation was a
weak positive (rs = .013 p = 0.914, df = 75) between receiving more time and attention
from medical experts and the purpose of the clinical research study. A weak positive
correlation (rs = .193, p = 0.096, df = 74) was found between receiving more time and
attention from medical experts and no risks are involved. The correlation between
receiving more time and attention from medical experts and doctor’s recommendation

17
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was a weak positive (rs = .013 p = 0.914, df = 75). A weak positive correlation (rs = .283
p = 0.013, df = 74) was found between receiving more time and attention from medical
experts and free treatment. The correlation was a moderate positive (rs = .344 p = 0.002,
df = 74) between receiving more time and attention from medical experts and the
convenience of the participation.
In the correlations conducted with potential risks and benefits, seven significant
correlations were found in total. A weak positive correlation (rs = .288, p = 0.011,
df = 76) was found between potential risks and benefits and the length of research
participation. The correlation was a moderate positive (rs = .408 p = 0.001, df = 76)
between potential risks and benefits and the types of medical procedures of the research.
A strong positive correlation (rs = .617, p = 0.001, df = 76) was found between potential
risks and benefits and the purpose of the clinical research study. The correlation was a
moderate positive (rs = .374 p = 0.001, df = 75) between potential risks and benefits and
no risks are involved in the research. A weak positive correlation (rs = .267, p = 0.019,
df = 75) was found between potential risks and benefits and doctor’s recommendation.
Similarly, a weak positive correlation (rs = .245, p = 0.032, df = 75) was found between
potential risks and benefits and free treatment. The correlation was a weak positive
(rs = .255 p = 0.025, df = 75) between potential risks and benefits and the convenience of
the participation.
In the correlations conducted with length of research participation, three
significant correlations were found in total. A strong positive correlation (rs = .649,
p = 0.001, df = 76) was found between the length of research participation and the types of
medical procedures of the research. The correlation was a moderate positive (rs = .333,
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p = 0.003, df = 76) between the length of research participation and the purpose of the
clinical research study. A weak positive correlation (rs = .094, p = 0.416, df = 75) was
found between the length of research participation and no risks are involved in the
research. The correlation was a weak positive (rs = .257, p = 0.024, df = 75) between the
length of research participation and doctor’s recommendation. Similarly, the correlation
was a weak positive (rs = .096, p = 0.406, df = 75) between the length of research
participation and free treatment. A weak positive correlation (rs = .172, p = 0.135,
df = 75) was found between the length of research participation and the convenience of
the participation.
In the correlations conducted with types of medical procedures of the research,
two significant correlations were found in total. A moderate positive correlation
(rs = .324, p = 0.004, df = 76) was found between the types of medical procedures of the
research and the purpose of the clinical research study. The correlation was a weak
positive (rs = .196, p = 0.088, df = 75) between the types of medical procedures of the
research and no risks are involved in the research. Similarly, the correlation was a weak
positive (rs = .138,

p = 0.231, df = 75) between the types of medical procedures of the

research and doctor’s recommendation. A weak positive correlation (rs = .195, p = 0.008,
df = 75) was found between the types of medical procedures of the research and free
treatment. The correlation between the types of medical procedures of the research and
the convenience of the participation was a weak positive (rs = .229, p = 0.045, df = 75).
In the correlations conducted with the purpose of the clinical research study, four
significant correlations were found in total. A moderate positive correlation (rs = .334,
p = 0.003, df = 75) was found between the purpose of the clinical research study and no
19
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risks are involved in the research. Similarly, a moderate positive correlation (rs = .314,
p = 0.005, df = 75) was found between the purpose of the clinical research study and
doctor’s recommendation. Also, the correlation between the purpose of the clinical
research study and free treatment was a moderate positive correlation (rs = .320,
p = 0.005, df = 75). The correlation was a weak positive (rs = .264, p = 0.020, df = 75)
between the purpose of the clinical research study and the convenience of the
participation.
In the correlations conducted with no risks are involved in the research, three
significant correlations were found in total. A weak positive correlation (rs = .298,
p = 0.008, df = 75) was found between no risk are involved in the research and doctor’s
recommendation. The correlation was a weak positive (rs = .290, p = 0.011, df = 75)
between no risks are involved in the research and free treatment. However, a moderate
positive correlation (rs = .469, p = 0.001, df = 75) was found between no risks are
involved in the research and the convenience of the participation.
The correlation was a moderate positive (rs = .431, p = 0.001, df = 75) between
doctor’s recommendation and free treatment. In addition, a moderate positive correlation
(rs = .300, p = 0.008, df = 75) was found between doctor’s recommendation and the
convenience of the participation. However, the correlation was a moderate positive
(rs = .461, p = 0.001, df = 75) between free treatment and the convenience of the
participation.
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Chi-Square Goodness-of-Fit
The hypothesis of this study proposed that there is no statistical difference in the
median rank score between CRA professionals and other post-graduate educated
participants, and therefore an exact chi-square goodness-of-fit test was performed on the
graduate sample of CRA to determine if this sample was representative of the postgraduates nationwide sample conducted by the CISCRP. There were significant
differences in the distribution of responses to participants’ willingness to participate in
clinical research X2(2) = 97.723, (p < .001). See Table 2 for a comparison of the clinical
research administration (CRA) Program graduate sample and the post-graduate of the
CISCRP sample data.
Table 2 A Comparison of Two Groups Regarding the Willingness to Participate in Clinical Trials
A Comparison of the Two Groups Regarding the Willingness to Participate
in Clinical Trials
CRA Graduates’
CISCRP Post-graduates’
Willingness

Willingness

I am not sure

N
6

%
7.6

N
6

%
1

Not at all willing

5

6.4

3

0.5

Not very willing

4

5.1

11

1,9

Somewhat willing

40

51.2

229

40.8

Very willing

23

29.4

311

55.5

Of the 78 CRA graduates that participated in this survey, six individuals were not
sure to participate, five individuals were not at all willing, four were not very willing, 40
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individuals were somewhat willing, and 23 individuals were very willing. In contrast, of
560 post-graduates of the CISCRP sample, six individuals were not sure to participate,
three individuals were not at all willing, 11 were not very willing, 229 individuals were
somewhat willing, and 311 individuals were very willing. Accordingly, the CISCRP postgraduates were more willing than CRA graduates while CRA graduates are somewhat
more willing to participate in clinical trials.
In order to identify the impact of professional knowledge and education on a
willingness to participate in clinical trials, several variables or facto rs should be
considered. First, a comparison was conducted between the CRA graduates sample and
the CISCRP sample with regard to their perception of clinical trials safety. See Table 3.
There were significant differences in the distribution of responses to participants’
perception of clinical trials safety. Over 95% of the responses of both groups were
characterized clinical trials as safe. Therefore, the perception of the safety of clinical trials
in CRA graduates and CISCRP post-graduates are the same.
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Table 3 Perception of Safety in Clinical Trials Among CRA and CISCRP
Perception of Safety in Clinical Trials Among CRA and CISCRP
CRA graduates’

CISCRP post-graduates’

perception of safety of

perception of safety of

clinical trials

clinical trials

Count

%

Count

%

Not safe

4

5.0%

7

1.25%

Safe

76

95%

553

98.75%

Total

80

100.0%

560

100.0%

Second, a comparison was conducted between CRA graduates and the postgraduates CISCRP sample on regard to the greater risk associated with the clinical trials.
See Table 4. Almost similar percentage of considering the possibility of side effects as the
greatest risk associated with clinical trial participation; CISCRP responses were 59%
while CRA graduates were 56%. However, the lowest percentages were not the same
among both groups; the lowest percentage was 1.3% in CRA sample, which no risks are
involved, and the lowest risk was 1% in CISCRP sample who thought that there was a
possibility of stopping treatments that proved some benefits.
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Table 4 The Greater Risk Associated with Clinical Trials Among CRA and CISCRP
The Greater Risk Associated with Clinical Trials Among CRA and CISCRP
CRA graduates’

CISCRP post-

perception of

graduates’ perception

the greater risk

of the greater risk

N

%

N

%

Possibility of side effects

45

56.3%

330

59%

Possibility of receiving a placebo or

8

10.0%

109

19%

Possible risks to my overall health

16

20.0%

91

16%

Possibility of stopping treatments that

4

5.0%

7

1%

1

1.3%

18

3%

inactive drug

may be providing some benefit to me
already
I do not believe there are risks

Another chi-square test was performed between the two groups. One-sample chisquare test was conducted on a willingness to participate, with a significant result being
found, χ2(4) = 97.723, p < .001. The two groups were statistically different, which is not
appropriate to compare between aggregated results of the CISCRP and individual
responses of CRA results. This indicated a significant difference between the observed
and expected frequencies, which are summarized in Table 5. These results indicate a
substantially greater likelihood of the CRA responding with I am not sure, Not at all
willing, Not very willing, and Somewhat willing as compared with the expected
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frequencies with a substantially lower likelihood of the CISCRP responding with Very
willing as compared with what was expected if the groups were equal. Therefore, if the
CRA followed the same distribution of the CISCRP, they should have the expected
frequencies of the CISCRP.
Table 5 One-Sample Chi-Square Analysis: Willingness to Participate in A Clinical Trial
One-Sample Chi-Square Analysis: Willingness to Participate in A Clinical Trial
Response Category

CRA

CISCRP

Residual

“Observed” N

“Expected” N

I am not sure

6

.8

5.2

Not at all willing

5

.4

4.6

Not very willing

4

1.5

2.5

Somewhat willing

40

31.9

8.1

Very willing

23

43.3

-20.3

Total

78

An additional chi-square test was conducted on a willingness to participate of the
sample of CRA to determine if this sample was previously participated in clinical trials.
As presented in Table 6, out of 78 participants, one graduate participated though he was
unsure of his willingness, and seven participants, who were somewhat willing,
participated in clinical trials. However, ten graduates were very willing to participate in
clinical trials, and13 participants already enrolled in clinical trials. Accordingly, 57
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participants had not participated previously in clinical trials regardless of their
willingness.
Table 6 Chi-Square Analysis: Willingness to Participate and Previous Participation
Chi-Square Analysis: Willingness to Participate and Previous Participation
Previously Participated in
Clinical Research Trials

Total

No

%

Yes

%

Willingness

I am not sure

5

83.3%

1

16.7%

6

100%

to

Not at all willing

5

100%

0

0.0%

5

100%

participate

Not very willing

4

100%

0

0.0%

4

100%

in Clinical

Somewhat

33

82.5%

7

17.5%

40

100%

Research

willing

Study

Very willing

10

43.5%

13

56.5%

23

100%

Total

57

73.1%

21

26.9%

78

100%

Odds Ratio
Table 7 presents the results of the cross tabulation conducted between CRA
graduates and post-graduate CISCRP measures. Seventy-two participants in the study of
CRA graduates responded to willingness question. However, the majority were willing to
participate in clinical trials (n = 63). A similar trend was found of the 554 participants of
the post-graduates CISCRP study. Among those with post-graduate CISCRP participants,
the majority were willing to participate (n = 540). The odds ratio of post-graduate
CISCRP respondents indicating willingness to participate in clinical research versus
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respondents from CRA graduates is 5.510 CI [2.292, 13.246], which was calculated as
(540/14)/(63/9). See Table 8. Post-graduate CISCRP were 5.51 times more likely to state
that they were willing to participate in clinical research than CRA graduates.
Table 7 Cross Tabulation Between Willing or Unwilling and Dataset
Cross Tabulation Between Willing or Unwilling and Dataset
Dataset
Post-Graduates
Groups

CRA Graduates

Total
CISCRP

Willing

63

540

603

Unwilling

9

14

23

Total

72

554

626

Table 8 Risk Estimate
Risk Estimate
95% Confidence Interval
Value

Lower

Upper

Odds Ratio for Willing or Unwilling

5.510

2.292

13.246

CRA graduates Dataset

3.745

2.138

6.562

CISCRP Post-Graduates Dataset

.680

.489

.944

N of Valid Cases

626
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Themes
CRA graduate results showed a strong theme regarding a medical or scientific
contribution. Out of 80 responses to the greatest benefit of participating in clinical trials,
49 responses were advancing the science, which was around 61.25%. See Figure 1. In
addition, about 65.82% strongly agreed on the scientific contribution as a perception of
how some people feel about clinical trials. See Figure 2.
70

1-Advance the science
61.25%

2-Save lives

60
3-Improve my condition
50

4-Provide money for participation
5-Compare available medications
with a new treatment

40

6-Provide free medication
30

7-Provide free medical care
8-Receive attention from doctors

20
13.75%
12.5%

9-Understand an inherited disease

10

10-There are no benefits
3.75%
0

1.25%

0

0

3.75%
0

0
Greatest Benefits

Figure 1. Greatest Benefit of Participating in Clinical Trials.
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70

65.82%

60

50

40

30
21.52%
20

10
3.8%

3.8%

5.06%

Strongly disagree

Somewhat disagree

Neutral

0
Somewhat Agree

Strongly agree

Figure 2. CRA Professionals’ Perception on How Some People are Contributing to
Science by Clinical Trials.
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V. Discussion
Discussion
The exact chi-square goodness-of-fit rejected the null hypothesis of this study. The
willing to participate in clinical trials was compared between the clinical research
administration (CRA) study sample and the post-graduate Center for Information and
Study on Clinical Research Participation (CISCRP) sample. The CRA graduates, who
were 67.47% of the study’s participants employed in clinical research, were somewhat
more willing to participate in clinical trials than the sample of the post-graduate CISCRP.
Although there was a significant difference between the two groups, it is difficult to state
which group was more willing due to the residual value were missing between the CRA
observed frequencies and the CISCRP expected frequencies. However, if we grouped the
responses of those who were willing and somewhat willing, 80.7% of the CRA graduates
were willing to participate in clinical trials, while the post-graduate CISCRP respondents
were 93% more willing. Therefore, there is a difference between the two groups.
In addition, the odds ratio test demonstrated that CRA graduates were 7 times
more likely to say that they were willing to participate in clinical trials, while CISCRP
post-graduates were 38.57 times more likely to say that they were willing to participate in
clinical trials. Accordingly, CISCRP post-graduates were 5.51 times more likely to state
that they were willing to participate in clinical trials than CRA graduates. The odds ratio
which is 5.51, supported the difference between the two groups as CRA graduates were
less willing to participate in clinical trials.
However, the study sample of CRA graduates showed that the potential
willingness to participate in clinical trials is highly associated with certain factors. These
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factors consisted of the following: age, time allocated to the doctor’s office, free treatment
and convenience of research participation, unavailability of other medical options, the
treatment’s assisting other patients, and the reasonability of the time commitment.
Interestingly, the influence of the time commitment and the convenience of the clinical
research could be due to demand jobs; 67.47% of the study’s participants were employed
in clinical research, which positively reflected on their behavior in and interpretations of
clinical trials. In addition, the effect of personal advantages on participation in clinical
trials was acceptable, as the study’s sample was more willing to participate if the
treatment was free of charge. Moreover, there was a positive correlation between trusting
physicians’ recommendations and the potential willingness to participate in clinical trials
if there were scientific or social benefits without minimal side effects associated with the
treatment, as well as sharing of a summary of research trial results with participants.
Accordingly, there were as potential willingness to participate in clinical trials in CRA
graduates regardless of their actual participation.
The results of the CRA graduates study acknowledged that the willingness to
participate in clinical trials affected the behavior of participants. About 17.5% of those
who were somewhat willing to participate and 56.5% who were very willing previously
participated in clinical trials. Thus, participants who were involved in clinical trials were
more willing to enroll in clinical studies. However, 73.1% of the total participants had not
participated previously in clinical trials regardless of their willingness. This result
indicated that their specialty and education affected their behavior of participation by
being more skeptical and more aware of the effect of some variables such as time
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commitment, side effects and adverse events. Therefore, potential participants with less
serious health conditions tend to be highly skeptical of participating.
Being skeptical has not always had a negative impact. The CRA graduates'
skepticism could be justified according to the importance of research objectives. In
addition, sometimes there is a need to be skeptical of science especially in clinical
research field due to the frequencies of errors or a large amount of expected and
unexpected adverse events in clinical trials. Thus, having scientific doubts implies
prioritizing evidence.
To support the skeptical of clinical research, a comparison of the CRA graduates
and CISCRP post-graduates indicated that the professional knowledge and education had
not impacted the overall perception of the safety profile of clinical trials. Both groups
were aware of the careful conduction of clinical trials as they are the fastest and safest
way to find treatments that work in people and to improve health. In addition, CRA
graduates and post-graduates CISCRP had the same level of risk involvement in clinical
trials. Both groups considered the possibility of side effects the greater risk. Due to their
education level, they were knowledgeable of the medical consequences and unpleasant
side effects that might occur during the participation in a clinical trial. Although both
groups had post-graduate degrees, one of the CRA graduates and 18 of the CISCRP postgraduates selected no risks are involved in clinical trials. Yet, the safety of clinical trials
and risks involvement in clinical trials are acknowledged.
In addition, CRA graduates’ results showed a strong theme, which is participation
in clinical trials was considered a medical or scientific contribution. First, according to
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CRA responses, the greatest benefit of participating in clinical trials is advancing the
science. Second, CRA graduates’ perceptions of how some people feel about clinical trials
strongly agreed that clinical trials considered a scientific contribution. This result
interpreted the reseaon of that CRA graduates were less willing to participate in clincal
trials as they were interested in the field as scientists more than clinical research
participants.
Research Limitations
All participants were invited to complete a shortened version of the CISCRP
published survey. Consequently, the language and items of the survey were not
customized to the appropriate knowledge of CRA graduates to ensure the exposure to the
same survey content of the two groups.
The research question could be answered, and the results could be accurately
interpreted if we could extract the individual responses from the CISCRP survey. Due to
the need of subgroup analysis of nationwide post-graduate in the CISCRP survey, it was
difficult to apply a new research question to their data. Therefore, the aggregated
responses were interpreted in a comparison of this research data.
This study has surveyed the alumni of the clinical research administration graduate
program at Eastern Michigan University, these respondents might not reflect all clinical
research professionals due to the low responses rate. Thus, the results could decrease the
possibility of the generalizability of the findings. In addition, the comprehension of the
nature of the clinical trials of this sample of the population may affect their perception of
participation in clinical trials positively or negatively.
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Suggestions for Further Research
More quantitative research on potential participants of those who are post-graduate
or have a clinical specialty, such as clinical research professionals, should be conducted.
Researchers should identify the barriers and motivations of professionals’ participation. In
addition, quantitative research should be conducted to test the time commitment of
clinical research professionals as a factor that influences their participation due to the high
percentage of the CRA sample who had not previously participate in clinical trials.
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VI. Conclusion
Overall, this study found that there is a significant difference between the clinical
research administration program graduates and the post-graduate Center for Information
and Study on Clinical Research Participation (CISCRP) in terms of their willingness to
participate in clinical trials. The CRA professionals were less willing to participate in
clinical trials than the post-graduate CISCRP. Although some factors must be considered
when attempting actual participation, knowledge and professional background affected
the willingness to participate in clinical trials. These results are justifiable, as the studied
sample is more knowledgeable about clinical research and have more concerns about their
participation. This conclusion must not affect the decision of recruiting clinical research
professionals in clinical trials. Rather, this work is intended to indicate some of the
differences between the two groups.
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Appendix A: IRB Exempt Approval
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Appendix B: Informed Consent for Participation in Clinical Research

Dear Participant,
You are invited to participate in this research as one of the alumni of the Clinical
Research Administration Graduate Program at Eastern Michigan University.
Research Objective: To identify your willingness to participate in clinical trials.
Voluntary Participation: You are completely free to choose whether to join the
study or not. You have the right of withdrawal from the study at any time. However, we
would appreciate your full participation.
Study Procedures: If you decide to participate in this study, you will fill out the
survey about your willingness to participate in clinical trials. It should take about 7-12
minutes of your time.
Expected Risks: There are no anticipated risks to participation.
Expected Benefits: You will not directly benefit from participating in this study.
Revision and Approval: The University Human Subjects Review Committee
(UHSRC) of Eastern Michigan University revised and approved this study.
Dissemination of Results: Results of this study may be presented publicly and/or
published in a scientific journal. A copy of the study results will be sent to all alumni via
E-mail.
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Confidentiality: This is an anonymous survey. The researcher and statistician
involved in this study will only have access to your responses. Otherwise, the information
you provide will be compiled with other data and reported statistically.
Contact Information: This study is graduate research for a Masters’ degree. If you
have any questions or concerns, you can contact the researcher, Rania Felemban, at
rfelemba@emich.edu. You can also contact the advisor, Dr. Irwin Martin, at
imartin2@emich.edu.
Statement of Consent: As a respondent, I understand my rights as a participant in
the above-described study and voluntarily consent to participate and follow the
requirements. Additionally, I understand the purpose, intent, and necessity of the study I
will be participating in, and I understand that if I do not, I may ask questions.
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Appendix C: Survey Form
1) Where do you currently reside?
☐ USA
☐ India
☐ Canada
☐ Europe
☐ Other (please specify) ……………….
2) Which race/ethnicity best describes you? (Please choose one only)
☐ Asian
☐ African
☐ Hispanic/Latino
☐ White/Caucasian
☐ Other (please specify) ……………….

3) What is your gender?
☐ Male
☐ Female

4) What is your age? (type age in box below)
………………………….
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5) How would you describe your employment status?
☐ Employed full-time
☐ Employed part-time
☐ Unemployed/looking for work
☐ Student
☐ Homemaker
☐ Retired
☐ Other (please specify) ……………….

6) Are you employed in clinical research now?
☐ Yes
☐ No
7) If no, what is your position?
……………….
8) What was your total household income before taxes during the past 12 months in
US dollars?
☐ Less than $25,000 USD
☐ $25,000 USD to $34,999 USD
☐ $35,000 USD to $49,999 USD
☐ $50,000 USD to $74,999 USD
☐ $75,000 USD to $99,999 USD
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☐ $100,000 USD to $124,999 USD
☐ $125,000 USD to $149,999 USD
☐ $150,000 USD or more
☐ Decline to respond

9) In your opinion, how safe are clinical research studies?
☐ Very safe
☐ Somewhat safe
☐ Not very safe
☐ Not at all safe

10) Which one of the following do you consider to be the greatest risk of
participating in a clinical research study? (select one)
☐ Possibility of side effects
☐ Possibility of receiving a placebo or inactive drug (sugar pill)
☐ Possibility of making my private medical information public
☐ Possible risks to my overall health
☐ Possibility of stopping treatments that may be providing some benefit to me already
☐ None - I do not believe there are risks
☐ Other (please specify) ……………….
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11) Which one of the following do you consider to be the greatest benefit of
participating in a clinical research study? (select one)
☐ May help advance science and the treatment of my disease/condition
☐ May help save or improve the lives of other patients with my disease/condition
☐ May help improve my disease/condition
☐ May provide monetary compensation (money) for participation
☐ May guide understanding of how available medications compare with a new treatment
☐ May provide free medication (if applicable in your country)
☐ May provide free medical procedures and care (if applicable in your country)
☐ May receive more care and attention from medical doctors and staff
☐ May help my family understand an inherited disease/condition
☐ None - I do not believe there are benefits
☐ Other (please specify) ……………….

12) Which TWO of the following reasons do you feel best describe why most people
participate in clinical research studies? (select up to TWO)
☐ To help others who may suffer from my disease/condition
☐ To follow-through on a doctor's recommendation to participate in a research study
☐ To receive monetary compensation (money)
☐ To help scientists understand more about how to treat my disease/condition
☐ To receive free medication (if applicable in your country)
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☐ To receive free medical procedures and care (if applicable in your country)
☐ To follow-through on a recommendation from my family or friends
☐ To find a cure or better treatment for my illness
☐ To help family members who may have this disease or condition in the future
☐ To receive more care and attention from medical doctors and staff
☐ Other (please specify) ……………….

13) The following statements describe how some people feel about clinical research
studies. Please indicate how strongly you agree or disagree with these statements.
People who participate in clinical research studies...

Strongly
disagree

Somewha
t disagree

Neutral

Somewha
t Agree

Strongly
agree

Have access to the
best doctors
Get the best
possible treatment
Are like
experimental test
subjects as
opposed to a
patient/person
Are making a
contribution to
science
Have a chance to
receive free
medicine and care
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Strongly
disagree

Somewha
t disagree

Neutral

Somewha
t Agree

Strongly
agree

Are taking a
gamble with their
health
Learn more about
their condition and
health
Spend a lot of time
at the doctor's
office
Are part of an
experiment to test
medications/treat
ments already
available to the
public
Are part of an
experiment to test
medications/treat
ments not already
available to the
public
Receive more time
and attention from
medical experts

14) In general, how willing would you be to participate in a clinical research study?
☐ Very willing
☐ Somewhat willing
☐ Not very willing
☐ Not at all willing
☐ I am not sure
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15) Before deciding to participate in a clinical research study, how important is
knowing each of the following types of information to you?

Not at all
important

Not very
important

Somewhat
important

Very
important

Potential risks and benefits
Physical location of the research
center (distance from home or
work)
Length of participation in the
clinical research study (time
commitment)
Number of study visits and types
of medical procedures required
Purpose of the clinical research
study
If I would have access to the
study drug after my participation
ended
If my confidentiality would be
protected
If I would receive a summary of
the study results after my
participation ended
Potential costs and
reimbursements
Hearing about the experiences
of previous research participants
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16) Have you ever tried to join (i.e., tried to participate in) a clinical research study?
☐ Yes
☐ No

17) Which of the following are reasons why you would not be willing to participate in
clinical research studies? (select all that apply)
☐ I do not want to risk getting an inactive drug (also known as sugar pill or placebo)
☐ I don't want to be treated like an experimental test subject as opposed to a
patient/person
☐ I am concerned about protecting my privacy
☐ I have concerns about the risks associated with clinical research studies
☐ Too much time is required to participate
☐ I am not interested in clinical research
☐ I do not know enough about clinical research
☐ It costs too much money to participate
☐ My health insurance does not cover the costs
☐ My family/caregiver did not want me to participate
☐ Online information convinced me not to participate
☐ I could not afford the time away from my job
☐ I have heard too many negative stories in the media and by word-of-mouth
☐ I do not think clinical research studies are ethical
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☐ I do not want to take a chance with my health
☐ It is too difficult for me to get to the research center
☐ I do not have any reason to participate
☐ There are no reasons in particular
☐ Other (please specify) ……………….

18) Please rate each of the factors below on their likelihood of influencing your
decision to participate in a clinical research study.

Not at
all
likely

Not very
likely

Neutral

Somewhat
likely

Very
likely

If I had a terminal illness
(incurable or fatal)
If I thought a study drug
might cure me
If I knew that I would
receive an active drug and
not an inactive substance
or sugar pill (placebo)
If I received money for
participating
If I knew the risks
associated with the
treatment
If I knew that it would not
cost me anything to
participate
If I knew there were no
risks involved
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Not at
all
likely

Not very
likely

Neutral

Somewhat
likely

Very
likely

If my doctor recommended
it
If the treatment were free
of charge to me
If I thought the
drug/treatment would help
me
If it were convenient for
me to participate (e.g.,
convenient appointment
times, the research center
was not too far away)
If I had a condition other
than a terminal illness
If there were no other
medical options available
to me
If there were minimal side
effects associated with the
treatment
If I thought the
drug/treatment would help
someone else in the future
If I already take a
drug/treatment
manufactured by the
pharmaceutical company
sponsoring the study
If I knew someone else
with my condition was
participating in the study
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Not at
all
likely

Not very
likely

Neutral

Somewhat
likely

Very
likely

If my family
recommended it
If it were recommended
via an online social
network or disease forum
If the time commitment
was reasonable
If I knew a summary of the
research study results
would be shared with me

19) Have you ever participated in (i.e., joined or enrolled) a clinical research study?
☐ Yes
☐ No
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Appendix D: Email Invitation

To: Clinical Research Administration Program Alumni
Subject: Clinical Research Survey
Date: Tue, Jan 10, 2017 at 8:14 AM

Good morning,
You have been identified as one of the alumni of the Clinical Research
Administration Graduate Program at Eastern Michigan University. You are invited to
participate in a study for a graduate research project. The purpose of this study is to assess
your willingness to participate in clinical trials.
I would appreciate your willingness to participate in the study, and I value your
feedback. This study consists of an on-line survey, and it should take about 7-12 minutes
of your time. Your feedback is highly appreciated.
If you have any questions or concerns, you can contact the researcher, Rania
Felemban, at rfelemba@emich.edu. You can also contact the advisor, Dr. Irwin Martin, at
imartin2@emich.edu.
To begin, please click the survey URL below:
https://www.surveymonkey.com/r/Felemban
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Thank you for taking the time to participate in the survey. We truly value the
information you have provided. By participating in this survey, you contributed to
enhancing subject enrollment in clinical trials and better understanding the barrier to
recruiting human subjects into clinical research.
Regards,
Rania Felemban
A graduate student
Clinical Research Master’s Program
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Appendix E: Email Reminder

To: Clinical Research Administration Program Alumni
Subject: Clinical Research Survey
Date: Tue, Jan 17, 2017 at 10:40 AM

Good morning,
This is a friendly reminder to participate in a study for a graduate research
project. If you are already participated, please disregard this E-mail.
You have been identified as one of the alumni of the Clinical Research
Administration Graduate Program at Eastern Michigan University. You are invited to
participate in a study for a graduate research project. The purpose of this study is to assess
your willingness to participate in clinical trials.
I would appreciate your willingness to participate in the study, and I value your
feedback. This study consists of an on-line survey, and it should take about 7-12 minutes
of your time. Your feedback is highly appreciated.
If you have any questions or concerns, you can contact the researcher, Rania
Felemban, at rfelemba@emich.edu. You can also contact the advisor, Dr. Irwin Martin, at
imartin2@emich.edu.
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To begin, please click the survey URL below:
https://www.surveymonkey.com/r/Felemban
Thank you for taking the time to participate in the survey. We truly value the
information you have provided. By participating in this survey, you contributed to
enhancing subject enrollment in clinical trials and better understanding the barrier to
recruiting human subjects into clinical research.

Regards,
Rania Felemban
A graduate student
Clinical Research Master’s Program
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